What does Pro Medicus specialise in?

Pro Medicus develops advanced radiology software, including solutions for medical imaging and healthcare data management.

What products does James Hardie focus on?

James Hardie specialises in fibre cement and gypsum building products used in construction across multiple regions.

How do PME and JHX differ in valuation approaches?

Pro Medicus is typically viewed through growth-focused metrics tied to technology adoption, while James Hardie is often assessed on its stability and strength in the construction sector.

PME and JHX Shares: Understanding Their Valuation in the ASX 200 Context

3 min read | August 17, 2025 05:49 PM PDT | By Team Kalkine Media

Google News:

PME and JHX Shares: Understanding Their Valuation in the ASX 200 Context — Image source: Shutterstock

Pro Medicus (ASX:PME)

Pro Medicus is widely recognised for its contribution to healthcare technology through advanced radiology software solutions. The company’s offerings cover radiology information systems, picture archiving and communication systems, as well as advanced visualisation tools.

Its flagship platform, Visage, allows radiologists to access and interpret large medical imaging files remotely. This ability supports faster diagnosis and decision-making, adding efficiency to modern healthcare services. With its solutions being utilised across hospitals and imaging centres worldwide, Pro Medicus maintains a strong footprint in the global healthcare technology space.

James Hardie Industries (ASX:JHX)

James Hardie Industries has established itself as a global leader in building solutions, specialising in fibre cement and gypsum products. The company operates in several key markets including North America, Europe, Australia, and New Zealand.

Fibre cement is particularly valued in construction due to its durability, resistance to fire and water damage, and minimal maintenance requirements. This makes the company’s product line appealing to both residential and commercial construction projects. With a substantial workforce and a global presence, James Hardie continues to strengthen its position in the building materials industry.

Comparing Valuations

When looking at valuations, both companies highlight different aspects of growth. Pro Medicus, often seen as a high-growth healthcare technology company, is valued strongly against its revenue metrics. This reflects both its innovation and the increasing demand for efficient medical imaging solutions.

On the other hand, James Hardie demonstrates stability through its building materials business. While it operates in a more traditional sector, its resilience and demand for fibre cement products continue to play a vital role in the company’s long-term outlook.

Although Pro Medicus and James Hardie belong to distinct industries, their valuations reveal unique stories of growth and resilience. Pro Medicus thrives on innovation in healthcare technology, while James Hardie continues to build on its strength as a leader in construction materials. Together, they reflect the diversity and depth within the Australian market.

Frequently Asked Questions

What does Pro Medicus specialise in?
Pro Medicus develops advanced radiology software, including solutions for medical imaging and healthcare data management.
What products does James Hardie focus on?
James Hardie specialises in fibre cement and gypsum building products used in construction across multiple regions.
How do PME and JHX differ in valuation approaches?
Pro Medicus is typically viewed through growth-focused metrics tied to technology adoption, while James Hardie is often assessed on its stability and strength in the construction sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.